Spreadsheet: 352f3aa7-a8ab-40a3-bbe2-d959299dc631
Sheet: Sheet1

# dsRNA | KD Phenotype | AGAP ID | Affymetrix probes | Previous ENSEMBL ID | Cluster | [NAME] (normalized) | Carcasses (normalized) | Heads (normalized) | Comments | InterPRO domains | Orthologs in Drosophila | FlyBase ID | [NAME] on Genome RNAi
A1 | Decreased phagocytosis | AGAP000182 | Ag.X.251.0_CDS_at | ENSANGT00000019333 | 1 | 2.8432367 | 0.72070223 | 0.4518353 |  | IPR001254 Peptidase_S1_S6;IPR001314 Peptidase_S1A | no
A2 |  | AGAP000220 | Ag.X.178.0_CDS_at | ENSANGT00000012758 | 4 | 7.674330999999998 | 0.7464619 | 0.69252884 |  | IPR000577 FGGY_kin | FBgn0031279 | CG3544 | Decreased viability
A3 |  | AGAP000249 | Ag.X.421.0_CDS_a_at; Ag.X.289.0_CDS_at | ENSANGT00000029522; ENSANGT00000012575 | 3 | 3.9401828 | 0.454288795 | 0.945038225 |  | IPR005201 Glyco_hydro_85 | FBgn0030839 | CG5613 | Decreased Flag-Mad nuclear accumulation; lethal
A4 |  | AGAP000305 | Ag.X.1164.0_at |  | 3 | 6.063104 | 0.9128951 | 0.8728162 | SPARC (growth factor/cell-cell signalling) | IPR002048 EF_hand_Ca_bd | FBgn0026562 | BM-40-SPARC | Lethal; altered muscle morphogenesis
A5 |  | [NAME] | Ag.X.162.0_CDS_at; Ag.X.162.1_a_at | ENSANGT00000010019 | 3 | 4.562779 | 0.5964444 | 0.96681774 |  |  | [NAME] | l(1)G0193 | Increased number of Chlamydia infected cells
A6 | increase LRIM1 expression | AGAP001954 | Ag.2R.3146.0_CDS_at |  |  |  |  |  | Psidin | IPR013026 TPR_region | FBgn0243511 | psidin | Lethal; altered muscle morphogenesis; altered regulation of Notch pathway
A7 | Decreased phagocytosis | AGAP002243 | Ag.2R.1527.0_CDS_at; Ag.2R.874.0_CDS_at | ENSANGT00000027712; ENSANGT00000006257 | 1 | 2.007013 | 0.64208084 | 0.7014785 |  | [NAME] BTB_POZ | FBgn0039955 | CG41099 | No Hits
A8 |  | AGAP002415 | Ag.2R.558.0_CDS_a_at | ENSANGT00000014292 | 2 | 4.486424 | 0.99116284 | 0.32045442 | GTPase (hemocyte activation) | [NAME] | FBgn0030893 | RhoGAP16F | No Hits
A9 |  | AGAP010658 | Ag.3L.1729.1_at |  |  |  |  |  |  | IPR005204 Hemocyanin, N-terminal; [NAME] centre-containing | FBgn0002562 | Lsp1alpha | miRNA reporter upregulated; decreased ERK phosphorylation
A10 | Decreased phagocytosis | AGAP003879 | Ag.2R.330.0_CDS_at | ENSANGT00000017920 | 6 | 0.8899256 | 1.6616763 | 0.9659291 | ATPase | IPR008388 ATPase_V1_S1 | FBgn0262515 | VhaAC45 | [NAME] intracellular infection; altered phenotype in 7 other RNAi screens
A11 |  | AGAP003898 | Ag.2R.2891.0_CDS_at | ENSANGT00000017205 | 4 | 8.358818000000001 | 0.8416641 | 0.9696395 | Leprecan |  | no
A12 |  | AGAP003960 | Ag.2R.1602.0_CDS_at; Ag.2R.566.0_CDS_at | ENSANGT00000015870; ENSANGT00000015844 | 3.1 | 2.76679135 | 0.8059181849999999 | 0.679435875 |  | IPR001254 Peptidase_S1_S6;IPR001314 Peptidase_S1A;IPR002967 Delta_tubulin | no
A13 |  | AGAP004017 | Ag.2R.1056.0_CDS_at | ENSANGT00000023264 | 4 | 16.491236 | 0.7801106 | 0.84800637 | LRR | IPR003591 [NAME] | no
A14 | Decreased phagocytosis | AGAP004928 | Ag.2L.351.0_CDS_at | ENSANGT00000024708 | 6 | 0.5774094 | 0.96158874 | 1.3636739 | TNF? [NAME] | IPR006629 LITAF;IPR006030 Mollsc_rhodpsn_C;IPR007087 Znf_C2H2 | FBgn0052280 | CG32280 | [NAME] intracellular infection; decreased G1 DNA content; increased number of mitotic cells
A15 |  | [NAME] | Ag.2L.472.0_CDS_at | ENSANGT00000010787 | 4 | 6.839807 | 0.77242273 | 0.8525459 |  | IPR000034 Laminin_B;IPR001791 Laminin_G;IPR002049 EGF_laminin;IPR006210 [NAME] Laminin_G_2;IPR013032 EGF_like_reg | FBgn0002526 | LanA | Upregulated Notch pathway after Notch stimulation
A16 |  | AGAP004993C | Ag.2L.472.0_CDS_at | ENSANGT00000010787 | 4 | 6.839807 | 0.77242273 | 0.8525459 |  | IPR000034 Laminin_B;IPR001791 Laminin_G;IPR002049 EGF_laminin;IPR006210 [NAME] Laminin_G_2;IPR013032 EGF_like_reg | FBgn0002526 | LanA | Upregulated Notch pathway after Notch stimulation
A17 |  | AGAP005174 | Ag.2L.461.0_CDS_at | ENSANGT00000015675 | 1 | 1.4851223 | 0.9633041 | 0.79728717 |  | IPR001680 WD40 | FBgn0033247 | Nup44A | ERK activation increased; upregulated Notch pathway; increased melanotic mass formation; decreased viability after Serratia marcescens infection 14
A18 |  | AGAP005227 | Ag.2L.1343.0_CDS_at | ENSANGT00000015785 |  |  |  |  |  | IPR000795 ProtSyn_GTP_bd;IPR001806 Ras_trnsfrmng;IPR000795 ProtSyn_GTP_bd;IPR004161 Transl_elong_EFTu/EF1A_2;IPR004160 Transl_elong_EFTu/EF1A_C | FBgn0027836 | Dgp-1 | Altered muscle morphogenesis; altered regulation of Notch pathway
A19 |  | AGAP005549 | Ag.2L.641.0_CDS_a_at; Ag.2L.641.1_UTR_a_at | ENSANGT00000017759 | 1 | 1.6383737 | 0.7180248 | 0.8538381 | Ig MHC | IPR003006 Ig_MHC;IPR004871 CPSF_A_C | FBgn0035162 | CG13900 | ERK activation increased; decreased calcium entry; siRNA reporter downregulated; upregulated Notch pathway; altered centrosome clustering; altered stem cell self-renewal
A20 |  | AGAP005551 | Ag.2L.747.1_CDS_a_at; Ag.2L.747.0_CDS_a_at | ENSANGT00000007196.a,b; ENSANGT00000025661 | 2 | 3.0751874 | 0.6562852 | 0.86100334 | Rab5 | IPR002653 Znf_A20;IPR003123 VPS9;IPR013995 VPS9_sub | FBgn0262937 | Rabex-5 | Altered centrosome clustering
A21 |  | AGAP005992 | Ag.2L.985.0_CDS_at | ENSANGT00000010747 | 3 | 4.95262 | 0.9631457 | 0.6450429 | [NAME] | IPR002401 Cyt_P450_E_grp-I;IPR001128 Cyt_P450;IPR002403 Cyt_P450_E_grp-IV | FBgn0000449 | dib | Decreased Flag-Mad nuclear accumulation
A22 | Increased phagocytosis | AGAP006769 | Ag.2L.591.0_CDS_a_at; Ag.2L.591.1_CDS_a_at | ENSANGT00000020342; ENSANGT00000027627 | 3 | 3.1642432 | 0.6268877 | 0.5097832 |  |  | FBgn0035282 | CG13936 | Decreased Hedgehog reporter activity; altered regulation of Notch pathway
A23 | increased LRIM1 expression | AGAP007499 | Ag.2L.1289.2_at; Ag.2L.1289.1_CDS_a_at | ENSANGT00000029645 | 4 | 15.755932 | 0.46806777 | 0.5652833 |  | IPR000644 CBS;IPR001807 Cl-channel_volt;IPR014743 Cl-channel_core | FBgn0033755 | ClC-b | Increased ERK phosphorylation after [NAME] and EGF stimulation
A24 |  | AGAP007540 | Ag.2L.1291.0_CDS_at | ENSANGT00000025800 | 1 | 1.4477571 | 0.7439521 | 1.0252224 |  | IPR002035 VWF_A | FBgn0031314 | CG4785 | Endo-siRNA, siRNA and miRNA reporter upregulated; decreased viability; downregulation of Notch pathway; completely lethal at pupal stage
A25 |  | AGAP008086 | Ag.3R.543.0_CDS_a_at | ENSANGT00000011665 | 1 | 2.2890446 | 0.64722186 | 1.0757391 | Humoral PRR, Lectin | IPR001431 Pept_M16_Zn_BS;IPR001220 [NAME] Pept_M16_N;IPR007863 [NAME] | FBgn0033235 | CG8728 | Developmentally lethal; altered Notch pathway
A26 | Increased phagocytosis | AGAP008492 | Ag.3R.2222.1_at; Ag.3R.2222.0_CDS_at | ENSANGT00000029563 |  |  |  |  |  |  | FBgn0032166 | CG4619 | No Hits
A27 |  | AGAP008521 | Ag.3R.359.0_CDS_at | ENSANGT00000011117 | 3 | 3.2275946 | 0.9868277 | 0.5287657 | Similar to low density lipoprotein receptor adaptor protein 1 | IPR006020 PTB_PID Phosphotyrosine interaction region | no
A28 |  | AGAP008908 | Ag.3R.253.0_CDS_at |  |  |  |  |  |  | IPR001680 WD40 | FBgn0001961 | Sop2 | Altered cell morphology; decreased [NAME] intracellular infection; altered muscle morphogenesis; decreased M. fortuitum infection; decreased E. coli phagocytosis; altered Notch pathway
A29 |  | AGAP008909 | Ag.3R.333.0_CDS_at | ENSANGT00000013993 | 1 | 1.3648154 | 0.6345629 | 0.99954593 |  | IPR008914 PEBP PhosphatidylEthanolamine-Binding Protein | FBgn0032453 | CG6180 | No Hits
A30 | increased LRIM1 basal activity | AGAP009119 | Ag.3R.815.1_at; Ag.3R.815.0_CDS_at | ENSANGT00000010637 | 1 | 1.3868104 | 0.5750225 | 0.9375283 |  | IPR001440 TPR_1;IPR006636 STI1_HS_bd;IPR013026 TPR_region;IPR013105 TPR_2 | FBgn0029676/FBgn0260484 | HIP-R/HIP | Increased G2 DNA content 8;
A31 |  | AGAP009200 | Ag.3R.33.0_CDS_a_at | ENSANGT00000026245 | 4.3 | 9.033850000000001 | 0.72332359 | 0.5573627649999999 | [NAME] (TNF) eiger | IPR000694 PRO_rich;IPR001442 Procollagn4_C;IPR002961 TNF_C;IPR008160 Collagen;IPR002961 TNF_C | no
A32 |  | AGAP009201 | Ag.3R.425.0_CDS_a_at | ENSANGT00000016652 | 4 | 8.157747 | 0.84049034 | 0.8277303 | Collagen (TNF) eiger | IPR001442 Procollagn4_C;IPR003979 [NAME] | no
A33 | Increased phagocytosis/Decreased CEC expression | AGAP009459 | Ag.3R.827.0_CDS_at | ENSANGT00000018666 | 3 | 5.513557 | 0.9728538 | 0.67883795 | [NAME] | IPR000719 Prot_kinase;IPR001245 Tyr_pkinase;IPR002290 Ser_thr_pkinase;IPR008271 Ser_thr_pkin_AS | [NAME] | cdc2 | Altered cell morphology; altered cell cycle regulation; altered cell morphology; increased [NAME] intracellular infection; reduced Clamydia infection; decreased Drosophila C virus and influenza replication; reduced ERK activation; downregulation of JAK/STAT pathway; increased mitochondrial activity; alterated Notch pathway; upregulated Wg pathway; decreased Wnt expression
A34 |  | AGAP009792 | Ag.3R.268.0_CDS_at | ENSANGT00000015835 | 3 | 4.7852254 | 0.91338927 | 0.47414318 |  | IPR000225 Armadillo;IPR000357 HEAT;IPR002652 Importin-a-like_IBB-bd | FBgn0011823 | Pen | Downregulated Notch pathway
[NAME] |  | AGAP010580 | Ag.3L.700.0_CDS_at | ENSANGT00000016239 | 4 | 24.886463 | 0.6017714 | 0.7977292 | Neurotransmitter-gated ion-channel ligand binding domain |  | FBgn0029147 | NtR | No Hits
A36 |  | AGAP010587 | Ag.3L.524.0_CDS_at | ENSANGT00000016273 |  |  |  |  |  | IPR001440 TPR_1;IPR003107 HAT;IPR013026 TPR_region;IPR013105 TPR_2 | FBgn0021847 | l(2)k14710 | Lethal; upregulated Notch pathway; altered differentiation in neural stem cells
A37 | Decreased phagocytosis | AGAP011223 | Ag.3L.654.0_CDS_at | ENSANGT00000011252 | 4 | 16.858324 | 0.78584254 | 0.8593975 |  | IPR002181 Fibrinogen_a/b/g_C | no
A38 |  | AGAP011984 | Ag.3L.1609.0_CDS_at | ENSANGT00000015302 | 4 | 9.402077 | 0.79295605 | 0.8710485 | Humoral PRR, Lectin | IPR000772 Ricin_B_lectin;IPR001173 Glyco_trans_2 | FBgn0035375 | pgant6 | Alterated protein secretion and Golgi organization; increased ERK phosphorylation
A39 |  | AGAP012034 | Ag.3L.2046.0_CDS_at | ENSANGT00000026523 | 3 | 5.4358253 | 0.819513 | 0.44222006 |  | IPR001314 Peptidase_S1A;IPR001254 Peptidase_S1_S6 | no
A40 |  | AGAP012614 | Ag.UNKN.1519.0_CDS_s_at; Ag.UNKN.1520.0_CDS_at | ENSANGT00000000070; ENSANGT00000015478 | 4 | 11.041295 | 1.1734793 | 0.7877436 |  | IPR001254 Peptidase_S1_S6;IPR001314 Peptidase_S1A | no
1 |  | AGAP000790 | Ag.X.1055.0_CDS_a_at | ENSANGT00000021342 | 3 | 21.733318 | 0.60298574 | 1.0035518 |  | signal;transmembrane;IPR002345 Lipocalin;IPR002968 A1-microglobln;IPR003057 Invtbrt_color;IPR002969 ApolipopD;IPR003087 N_gelatinase; | FBgn0030334 | [NAME] | No Hits
2 |  | AGAP004016 | Ag.2R.1328.0_CDS_at | ENSANGT00000014345 | 4 | 18.309685 | 0.72139156 | 0.50085497 | LRR | IPR001611 LRR; IPR003591 LRR_typ | no
3 |  | AGAP012000 | Ag.3L.2035.0_CDS_s_at | ENSANGT00000016460 | 4 | 16.530178 | 0.48577788 | 0.63121545 |  | IPR002181 Fibrinogen_a/b/g_C | no
4 |  | AGAP006743 | Ag.2L.1451.0_CDS_at | ENSANGT00000020316 | 4 | 16.1865 | 0.40445495 | 1.1358438 |  | IPR002181 Fibrinogen_a/b/g_C | no
5 |  | AGAP001508 | Ag.2R.677.0_CDS_at | ENSANGT00000009630 | 4 | 16.066338 | 0.894102 | 0.6438381 |  | signal | no
6 | increased LRIM1 expression | AGAP009762 | Ag.3R.239.0_CDS_at | ENSANGT00000014402 | 4 | 13.729649 | 0.51806307 | 0.85543007 | Similar to Nimrod | transmembrane;IPR006210 EGF;IPR001881 EGF_Ca_bd;IPR013032 EGF_like_reg;IPR003341 Cys_rich_tripleX | FBgn0028939/FBgn0243514 | nimC2/eater | Altered Notch pathway; no effect on dsRNA uptake/Decreased Flag-Mad nuclear accumulation; decreased intracellular [NAME] infection; increased P-JNK protein expression with PGN
7 |  | AGAP009387 | Ag.3R.634.0_CDS_s_at | ENSANGT00000026294 | 4 | 10.321435 | 0.61298144 | 0.99822015 |  | signal;transmembrane;IPR004272 Odorant_bd | no
8 | increased CEC expression | AGAP006771 | Ag.2L.664.0_UTR_at | ENSANGT00000020363 | 4.3 | 9.264997000000001 | 0.82233465 | 0.95298266 | [NAME]? (JNK pathway) | transmembrane;IPR006052 TNF_family | FBgn0033483 | egr | No Hits
9 |  | AGAP000376 | Ag.X.148.0_CDS_at | ENSANGT00000021949 | 4 | 8.934975 | 0.8458995 | 0.45630538 |  | signal;transmembrane;IPR001156 Peptidase_S60 | FBgn0022355 | Tsf1 | Decreased ERK phosphorylation after [NAME] and EGF stimulation
10 | Increased phagocytosis | AGAP006914 | Ag.2L.1460.0_CDS_at | ENSANGT00000021698 | 4 | 8.827008000000001 | 0.43928185 | 1.3024791 |  | IPR002181 Fibrinogen_a/b/g_C | no
11 | Increased phagocytosis | AGAP011197 | Ag.3L.449.0_CDS_at | [NAME] | 4 | 8.543608 | 0.51707464 | 0.59416234 | [NAME] | IPR002345 [NAME]g_C | no
12 |  | AGAP007312 | Ag.2L.416.0_CDS_at | ENSANGT00000016759 | 4 | 8.051081000000002 | 0.8847787 | 0.5807465 |  | signal;transmembrane | no
13 | decreased CEC expression | AGAP009231 | Ag.3R.819.0_UTR_at | ENSANGT00000010584 | 4 | 7.141202 | 0.88826835 | 0.8893455 |  | [NAME] | no
14 |  | AGAP002594 | Ag.2R.345.0_CDS_a_at | ENSANGT00000010605 | 4 | 7.101287 | 1.0678258 | 0.48450983 |  | IPR002345 Lipocalin;IPR002449 Retinol_bd;IPR002972 PstgldnD_synth;IPR003057 Invtbrt_color;IPR002969 ApolipopD;IPR000566 Lipocln_cytFABP;signal;IPR003087 N_gelatinase | no
15 |  | AGAP001662 | Ag.2R.1664.0_CDS_at | ENSANGT00000022061 | 4 | 6.5033693 | 0.7562974 | 0.75058687 |  | IPR013032 EGF_like_reg;IPR013106 Ig_V-set;IPR007110 Ig-like;IPR008197 WAP;IPR013098 Ig_I-set;IPR013151 Immunoglobulin;IPR003598 Ig_sub2;IPR003599 Ig_sub | FBgn0003137 | Ppn | Embryonic lethal or no offspring; lethal (pupal stage)
16 |  | AGAP001243 | Ag.2R.1811.0_CDS_at | ENSANGT00000023056 | 3 | 5.8417463 | 0.7460644 | 1.0004381 |  | IPR002110 ANK | no
17 |  | AGAP012337 | Ag.3L.877.0_CDS_at | ENSANGT00000028160 | 3 | 5.3206835 | 0.998041 | 0.780551 |  |  | no
18 |  | AGAP009380 | Ag.3R.496.0_CDS_at | ENSANGT00000025171 | 3 | 5.2717295 | 0.8232537 | 0.44621965 |  | IPR001071 CRAL_bd_toc_tran;IPR001251 CRAL_bd_TRIO_C | no
19 |  | AGAP007039 | Ag.2L.528.0_CDS_at | ENSANGT00000015066 | 3.1 | 5.001879 | 0.8374601 | 0.57006174 |  | signal;IPR001611 LRR;IPR003591 LRR_typ | no
20 |  | AGAP011765 | Ag.3L.233.2_CDS_a_at | [NAME] | 3 | 4.7762537 | 0.9472809 | 0.6123453 |  | [NAME], type I, IPR002861 Reeler region, IPR009465 Spondin, N-terminal, IPR002223 Proteinase inhibitor I2, Kunitz metazoa; IPR001007 VWF_C | FBgn0026721 | fat-spondin | No Hits
21 |  | AGAP008013 | Ag.3R.276.0_CDS_a_at | ENSANGT00000012392 | 2 | 4.5580606 | 1.0301431 | 0.40649164 |  |  | [NAME] | fon | No Hits
22 |  | AGAP009556 | Ag.3R.1917.0_CDS_at | ENSANGT00000029396 | 3 | 4.232131 | 0.94547415 | 0.63687223 |  | signal;IPR002181 Fibrinogen_a/b/g_C | FBgn0030163 | CG1791 | Embryonic lethal or no offspring; increased ERK phosphorylation after [NAME] and EGF stimulation
23 |  | AGAP012386 | Ag.3L.1276.0_CDS_a_at | ENSANGT00000008964 | 3 | 4.221101 | 0.78535545 | 0.75391656 | Similar to Nimrod | IPR013032 EGF_like_reg;IPR003341 [NAME] EGF_Ca_bd;IPR006210 EGF | FBgn0028939 | [NAME] | Altered Notch pathway; no effect on dsRNA uptake
24 |  | AGAP011668 | Ag.3L.1200.0_CDS_at | ENSANGT00000028145 | 2 | 4.041669 | 1.094768 | 0.38230127 |  |  | no
25 | Decreased phagocytosis | AGAP000095 | Ag.X.896.0_CDS_at | ENSANGT00000008160 | 3 | 3.9686613 | 0.68581235 | 0.8856634 |  | transmembrane;IPR007632 DUF590 | FBgn0030349 | CG10353 | Altered mitochondrial Ca2+ and H+ regulation
26 |  | AGAP005612 | Ag.2L.1068.0_CDS_at | ENSANGT00000018284 | 2 | 3.9294891 | 1.1388474 | 0.44106203 |  | signal | no
27 |  | AGAP000806 | Ag.X.151.0_CDS_at | ENSANGT00000021380 | 3 | 3.731869 | 0.94141465 | 0.549751 |  | signal;transmembrane;IPR002181 Fibrinogen_a/b/g_C | no
28 | Increased phagocytosis/Decreased LRIM1 expression/Increased LRIM1 basal activity | AGAP001381 | Ag.2R.598.0_CDS_a_at | ENSANGT00000016875 | 4 | 3.5595958 | 0.7394299 | 0.74500895 | Laminin (EGF-like) | IPR013032 EGF_like_reg;IPR002049 EGF-like, laminin IPR008211 Laminin, N-terminal;IPR001881 EGF_Ca_bd;IPR006210 EGF;IPR013015 Laminin_IV | FBgn0261800 | [NAME] | Decreased viability after Serratia marcescens infection; lethal; altered muscle and heart morphogenesis; altered regulation of Notch pathway
29 |  | AGAP009490 | Ag.3R.1119.0_CDS_at | ENSANGT00000025538 | 3 | 3.4113123 | 0.8820544 | 0.6455952 |  | [NAME] | FBgn0037481 | MAGE | No Hits
30 |  | AGAP006327 | Ag.2L.342.0_CDS_at | ENSANGT00000013779 | 2 | 3.247657 | 0.9550416 | 0.14194399 |  | signal;IPR001611 LRR;IPR003591 LRR_typ | no
31 | increased CEC expression | AGAP010531 | Ag.3L.328.0_CDS_at | ENSANGT00000020573 | 2 | 3.231848 | 0.7361271 | 0.41470674 |  | signal;IPR002181 Fibrinogen_a/b/g_C | no
32 |  | AGAP012352 | Ag.3L.260.0_CDS_at | ENSANGT00000020083 | 1 | 3.1514015 | 1.0399147 | 0.506575 |  | signal;IPR003172 MD-2_lipid-recog | FBgn0039800 | Npc2g | Altered muscle morphogenesis
33 |  | AGAP005611 | Ag.2L.876.0_CDS_a_at | ENSANGT00000017826 | 3 | 3.080786 | 0.9751482 | 0.7635775 |  | signal;transmembrane | no
34 |  | AGAP002593 | Ag.2R.1272.0_CDS_at | ENSANGT00000028106 | 2 | 3.0514483 | 0.9890373 | 0.37566838 |  | IPR002345 Lipocalin;IPR002449 Retinol_bd;signal;IPR003057 Invtbrt_color;IPR013208 Lipocalin_2;IPR002969 ApolipopD;IPR003087 N_gelatinase | no
35 |  | AGAP011503 | Ag.3L.825.0_CDS_a_at | ENSANGT00000014959 | 3 | 3.0489402 | 0.7432476 | 0.5508869 |  | signal;IPR001611 LRR | no
36 |  | AGAP009146 | Ag.3R.164.0_CDS_at | ENSANGT00000021506 | 2 | 2.8122628 | 1.0266922 | 0.7337172 |  | signal | no
37 | increased LRIM1 basal activity | AGAP002186 | Ag.2R.759.0_CDS_at | ENSANGT00000006309 | 3 | 2.754167 | 0.8071359 | 0.96987265 |  | IPR013032 EGF_like_reg;IPR000152 Asx_hydroxyl_S;IPR006209 EGF_like;IPR001491 Thrmbomoduln;IPR013091 EGF_Ca_bd_2;IPR001881 EGF_Ca_bd;IPR000033 LDLR;IPR002172 LDL_rcpt_A;IPR006210 EGF | FBgn0051092 | LpR2 | Increased melanotic mass formation; decreased fly viability
38 |  | AGAP013527 | Ag.2R.1474.0_CDS_at | ENSANGT00000025832 | 3 | 2.6411417 | 0.84007376 | 0.912668 |  |  | no
39 |  | AGAP007314 | Ag.2L.669.0_CDS_at | ENSANGT00000016687 | 3 | 2.584007 | 0.8329982 | 0.59064853 |  | signal;transmembrane | no
40 |  | AGAP006275 | Ag.2L.178.0_CDS_a_at | ENSANGT00000021680 | 2 | 2.5508213 | 0.59471285 | 0.3691809 |  | signal | no
41 |  | AGAP008923 | Ag.3R.2331.0_CDS_at | ENSANGT00000021979 | 2 | 2.5384479 | 0.57327425 | 0.9708393 |  | signal | no
42 |  | AGAP009184 | Ag.3R.1860.0_CDS_at | ENSANGT00000022610 | 3 | 2.536414 | 0.72272867 | 0.67277163 |  | IPR002181 Fibrinogen_a/b/g_C | no
43 |  | AGAP009311 | Ag.3R.988.0_CDS_at | ENSANGT00000028550 | 3 | 2.5207443 | 0.91259897 | 0.6913553 |  | IPR001071 CRAL_bd_toc_tran;IPR008273 CRAL_bd_TRIO_N | FBgn0032785 | CG10026 | No Hits
44 |  | AGAP003304 | Ag.2R.332.0_CDS_at | ENSANGT00000014526 | 3 | 2.28169 | 1.0732565 | 0.6590505 |  | [NAME] | no
45 |  | AGAP002268 | Ag.2R.2171.0_CDS_at | ENSANGT00000021854 | 2 | 2.2703636 | 0.89075184 | 0.5203071 |  | IPR000152 Asx_hydroxyl_S;IPR006209 EGF_like;IPR013091 EGF_Ca_bd_2;IPR001881 EGF_Ca_bd;IPR000001 Kringle;IPR006210 EGF | no
46 |  | AGAP011387 | Ag.3L.310.0_CDS_s_at | ENSANGT00000011371 | 1 | 2.1654017 | 0.99133956 | 0.8001546 |  | IPR001680 WD40 | FBgn0036460 | CG5114 | ERK activation increased; altered Notch pathway; increased P-JNK protein expression with PGN
47 |  | AGAP000615 | Ag.X.512.0_CDS_at | ENSANGT00000019196 | 1 | 2.118765 | 0.80925685 | 0.97350216 |  | transmembrane;IPR006597 Sel1_like | FBgn0028475 | Hrd3 | Upregulation of Notch pathway
48 |  | AGAP009817 | Ag.3R.2547.0_CDS_at | ENSANGT00000015861 | 1 | 2.0931823 | 0.97560334 | 0.7281063 |  | [NAME] | no
49 |  | AGAP009642 | Ag.3R.230.1_UTR_a_at | ENSANGT00000022240 | 1 | 2.0525172 | 0.8691725 | 0.82865083 |  | IPR001107 Band_7;IPR000163 Prohibitin | FBgn0010551 | l(2)03709 | Altered cytokinesis, protein secretion and Golgi organization; ERK activation reduced; decreased ERK phosphorylation after EGF stimulation; lethal (pupal and adult stages)
50 |  | AGAP000911 | Ag.X.210.0_CDS_at | ENSANGT00000021427 | 1 | 1.983857 | 0.99902797 | 0.8001491 |  | signal;transmembrane | FBgn0035440 | CG14969 | No Hits
51 |  | AGAP005693 | Ag.2L.225.0_UTR_at | ENSANGT00000021822 | 2 | 1.9317664 | 0.8994159 | 0.5296792 |  | IPR001611 LRR;IPR003591 LRR_typ | no
52 |  | AGAP007313 | Ag.2L.1017.0_CDS_at | ENSANGT00000022987 | 1 | 1.8937023 | 0.92056704 | 0.7016405 |  | signal;transmembrane | no
53 |  | AGAP001798 | Ag.2R.3123.0_CDS_at | ENSANGT00000018359 | 1 | 1.8732716 | 0.873015 | 0.9428806 |  | IPR000436 Sushi_SCR_CCP;IPR001254 Peptidase_S1_S6;IPR002172 LDL_rcpt_A;IPR001314 Peptidase_S1A | FBgn0051217 | modSP | Less inclusions in Chlamydia infection; decreased Flag-Mad nuclear accumulation
54 |  | AGAP001242 | Ag.2R.1810.0_CDS_at | ENSANGT00000013862 | 1 | 1.8658844 | 0.13696985 | 1.0245122 |  | [NAME] Ig_I-set;IPR013151 Immunoglobulin;IPR013106 Ig_V-set;IPR003596 Ig_V-set_sub;IPR003598 Ig_sub2;IPR003599 Ig_sub;IPR009134 VEGFR_N | FBgn0053512 | dpr4 | Decreased Flag-Mad nuclear accumulation; upregulated Notch pathway; altered muscle morphogenesis
55 |  | AGAP009859 | Ag.3R.314.0_CDS_at | ENSANGT00000014861 | 2 | 1.8244611 | 0.9496088 | 0.18362801 |  |  | no
56 |  | AGAP004557 | Ag.2R.1228.0_CDS_at | ENSANGT00000012199 | 1 | 1.7082084 | 1.0107036 | 0.80696714 |  | IPR001680 WD40;IPR007319 Utp21 | [NAME] | CG9799 | Increased ERK phosphorylation after EGF stimulation; muscle and bristle morphology defects, lethal;
57 |  | AGAP001148 | Ag.2R.672.0_CDS_a_at | [NAME] | 1 | 1.6451161 | 0.7596487 | 0.9788354 |  | IPR000108 [NAME] PRO_rich;IPR001452 SH3;IPR013315 Spectrin_alpha | FBgn0010877 | l(3)05822 | No Hits
58 |  | AGAP006377 | Ag.2L.585.0_CDS_at | ENSANGT00000013072 | 1 | 1.6143508 | 0.8355994 | 0.8494534 |  | signal;transmembrane | no
59 |  | AGAP003220 | Ag.2R.1730.0_CDS_s_at | ENSANGT00000014719 | 1 | 1.596307 | 0.87407833 | 0.8455076 |  | IPR004119 DUF227;IPR012877 DUF1679_CAEspp | FBgn0030060 | CG2004 | No Hits
60 | increased LRIM1 expression | AGAP003473 | Ag.2R.894.0_CDS_a_at | ENSANGT00000014362 | 1 | 1.5582199 | 0.804098 | 0.49853927 |  | signal;transmembrane | no
61 |  | AGAP010325 | Ag.UNKN.59.0_CDS_at | ENSANGT00000024749 | 2 | 1.5118423 | 0.94369775 | 0.3283862 |  | [NAME] MIP;IPR012269 AQP | FBgn0034883 | CG17664 | Decreased viability; decreased viability after Serratia marcescens infection; altered Notch pathway
62 |  | AGAP007665 | Ag.2L.358.0_CDS_at | [NAME] | 1 | 1.5080731 | 0.835554 | 0.99341017 |  | signal;transmembrane;IPR009832 DUF1397 | FBgn0030740 | CG9917 | No Hits
63 |  | AGAP003304 | Ag.2R.3382.0_CDS_s_at | ENSANGT00000017918 | 1 | 1.3517011 | 0.8377655 | 0.7430178 |  | [NAME] | no
64 |  | AGAP008813 | Ag.3R.882.0_CDS_at | ENSANGT00000001123 | 1 | 1.3387499 | 0.75461596 | 1.0735259 |  | IPR000719 Prot_kinase;IPR001245 Tyr_pkinase;IPR002290 Ser_thr_pkinase;IPR008266 Tyr_pkinase_AS;IPR003598 Ig_sub2;IPR003599 [NAME] Ig_I-set;IPR013151 Ig | FBgn0032006 | [NAME] | Altered cell morphology; decreased triglyceride expression, Calcium entry, protein secretion and altered Golgi organization; decreased C. trachomatis infection; decreased cell number and viability and altered cell cycle and morphology; ERK activation reduced; increased IMD reporter activity; upregulated Notch pathway; increased P-JNK protein expression with PGN; altered ERK phosphorilation; increased Wnt reporter activity; increased viability after Serratia marcescens infection
65 |  | AGAP012432 | Ag.UNKN.84.0_CDS_a_at | ENSANGT00000000667 | 1 | 1.3237928 | 0.61130095 | 1.1374105 |  | transmembrane;IPR008564 DUF846_euk; | FBgn0035944 | CG5021 | Altered Notch pathway
66 |  | AGAP010934 | Ag.3L.1790.0_CDS_at | ENSANGT00000027303 | 1 | 1.3171965 | 0.8620697 | 0.60584027 |  | IPR002110 ANK;IPR001360 Glyco_hydro_1 | no
67 |  | AGAP005761 | Ag.2L.645.0_CDS_a_at | ENSANGT00000004406 | 1 | 1.2616756 | 0.586251 | 1.0022421 |  | [NAME] | FBgn0029737 | CG6903 | Endo-siRNA reporter downregulated
68 | Decreased phagocytosis | AGAP008500 | Ag.3R.353.0_CDS_a_at | ENSANGT00000019960 | 1 | 1.1529633 | 0.89479554 | 0.95543784 |  | [NAME] | no
69 |  | AGAP003534 | Ag.2R.1589.0_CDS_at | ENSANGT00000023319 | 1 | 1.1165168 | 0.96156645 | 0.6277124 |  | [NAME] | FBgn0053169 | CG33169 | Altered Notch pathway; altered muscle morphogenesis
70 |  | AGAP005888 | Ag.2L.226.0_CDS_at | ENSANGT00000014131 | 1 | 1.0810685 | 0.98965436 | 0.44636127 | Kininogen | signal;transmembrane;IPR002395 Kininogen | no
71 |  | AGAP009259 | Ag.3R.1107.0_CDS_at | ENSANGT00000012287 | 1 | 1.6468505 | 0.91091603 | 0.8262371 |  | transmembrane;IPR001981 Colipase;IPR004299 MBOAT_fam | FBgn0031815 | frj | No Hits